Results 241 to 250 of about 1,320,527 (284)
Drug Insight: eplerenone, a mineralocorticoid-receptor antagonist
Nature Clinical Practice Endocrinology & Metabolism, 2008 Increasing recognition of the role of aldosterone in cardiovascular disease has been supported by a significant body of evidence from animal models. This evidence has been translated into clinical practice, and large-scale, randomized, placebo-controlled trials have confirmed the beneficial effects of mineralocorticoid blockade in patients with heart ...
McManus, Frances +2 more
openaire +4 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Adverse Effects of Mineralocorticoid Receptor Antagonist Administration
Current Pharmaceutical Design, 2019Background: Mineralocorticoid receptor antagonists consist of a class of drugs with pleiotropic beneficial effects in several cardiovascular diseases. However, physicians frequently overlook their use due to the adverse effects of such agents. Objectives: To determine the adverse effects of mineralocorticoid receptor antagonists and to suggest ...
Leonidas Poulimenos +1 more
exaly +3 more sources
Mineralocorticoid receptor antagonists
Current Hypertension Reports, 2007With an increasingly aging population, the need for effective treatment of cardiovascular diseases (eg, heart failure, hypertension, and ischemic heart disease) cannot be overemphasized. The vital importance of mineralocorticoid receptor antagonists for treating cardiovascular conditions has only been appreciated in the last decade. The re-emergence of
Parthasarathy, Hari Krishnan +1 more
openaire +3 more sources
Mineralocorticoid receptor antagonists
2023Abstract Hypertension, post-myocardial infarction, and heart failure are the cardiovascular clinical syndromes where mineralocorticoid receptor antagonists (MRAs) have shown a beneficial effect. Most guidelines, while recommending MRAs, do not make a clear recommendation as to which MRAs should be used, how doses should be titrated, or ...
Bertram Pitt +2 more
openaire +1 more source
Mineralocorticoid receptor antagonists
2022Abstract This chapter studies the use of aldosterone antagonists, also known as mineralocorticoid receptor antagonists (MRAs), in chronic heart failure (CHF). Overall, the results for aldosterone blockade in CHF due to left ventricular systolic dysfunction—now called heart failure with reduced ejection fraction (HFrEF)—have been very ...
S. Rekhraj +2 more
openaire +1 more source
Nonsteroidal antagonists of the mineralocorticoid receptor
Current Opinion in Nephrology and Hypertension, 2015The broad clinical use of steroidal mineralocorticoid receptor antagonists (MRAs) is limited by the potential risk of inducing hyperkalemia when given on top of renin-angiotensin system blockade. Drug discovery campaigns have been launched aiming for the identification of nonsteroidal MRAs with an improved safety profile.
Peter, Kolkhof +2 more
openaire +2 more sources
Current Vascular Pharmacology, 2012
Several lines of evidence suggest a detrimental effect of aldosterone excess on the development of metabolic alterations. Glucose metabolism derangements due to aldosterone action are frequently observed not only in patients with primary aldosteronism but also in patients with obesity. A contribution to the hyperaldosteronism observed in obese subjects
Ronconi, Vanessa +5 more
openaire +2 more sources
Several lines of evidence suggest a detrimental effect of aldosterone excess on the development of metabolic alterations. Glucose metabolism derangements due to aldosterone action are frequently observed not only in patients with primary aldosteronism but also in patients with obesity. A contribution to the hyperaldosteronism observed in obese subjects
Ronconi, Vanessa +5 more
openaire +2 more sources